T. Rowe Price Associates
NBIX icon

T. Rowe Price Associates’s Neurocrine Biosciences NBIX Stock Holding History

T. Rowe Price Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-93,700
Closed -$7.27M – 2570
2017
Q4 		$7.27M Sell
93,700
-275,300
-75% -$18.8M ﹤0.01% 1388
2017
Q3 		$22.6M Buy
+369,000
New +$19.5M ﹤0.01% 1137

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's NBIX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Neurocrine Biosciences (NBIX) stake by 92% in Q1 2026, selling an estimated $228M and leaving 151,256 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1038.

T. Rowe Price Associates first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $815M in Q2 2020. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • T. Rowe Price Associates held 151,256 shares of Neurocrine Biosciences worth $19.9M as of Q1 2026.
  • T. Rowe Price Associates sold 1,720,984 Neurocrine Biosciences shares in Q1 2026, an estimated $228M.
  • Neurocrine Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1038 holding.
  • T. Rowe Price Associates first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Neurocrine Biosciences position peaked at $815M in Q2 2020.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.